Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies (Nasdaq: ADPT) announced FDA Emergency Use Authorization for its T-Detect COVID test, the first T cell-based diagnostic for detecting prior SARS-CoV-2 infections. The test demonstrated 97.1% sensitivity and 100% specificity. Developed in collaboration with Microsoft, T-Detect COVID allows individuals uncertain about past infections to confirm their status, marking a significant milestone in diagnostic testing. This technology leverages T cells' capabilities for improved disease detection and is expected to pave the way for future diagnostic tests across various diseases.

Adaptive Biotechnologies Corporation announced its participation in the Cowen 41^st Annual Healthcare Conference, scheduled for March 2, 2021. The company will engage in a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.

Interested parties can access a live and archived webcast on their website. Adaptive focuses on utilizing the adaptive immune system to develop clinical products for diagnosing and treating diseases, with a strong emphasis on precision and individual patient care.

Adaptive Biotechnologies (Nasdaq: ADPT) announced its financial results for Q4 and the full year 2020, reporting revenues of $30.2 million for Q4 and $98.4 million for the year, marking increases of 25% and 16% respectively. The company launched T-Detect COVID, a T-cell based test for COVID-19, currently under FDA review for Emergency Use Authorization. Operating expenses rose 54% to $74.4 million in Q4, while net loss increased to $44.6 million. Despite these challenges, cash reserves stand strong at $806.8 million as of year-end.

Adaptive Biotechnologies (Nasdaq: ADPT) announced an expanded collaboration with Labcorp (NYSE: LH) to enhance patient access to its immune-driven clinical diagnostics. This includes commercial agreements for the clonoSEQ® and immunoSEQ® assays and a lab services agreement for the T-Detect COVID test. The collaboration builds on a prior agreement from May 2020, allowing blood collection for clonoSEQ and T-Detect at nearly 2,000 Labcorp patient service centers. Labcorp will promote clonoSEQ in hematology-oncology clinics and prepare to offer T-Detect COVID once it obtains Emergency Use Authorization from the FDA.

Adaptive Biotechnologies (Nasdaq: ADPT) has launched T-Detect COVID, a pioneering T-cell based test for confirming recent or past COVID-19 infections. This innovative test, currently under FDA review for Emergency Use Authorization, reportedly outperforms existing antibody tests. T-Detect is available for patients through nearly 2,000 Labcorp locations or via mobile phlebotomy services. The test leverages research from Microsoft’s TCR-Antigen Map to enhance early diagnosis of COVID-19 and potentially other diseases.

Adaptive Biotechnologies has announced a multi-year collaboration with AstraZeneca to extend its immunoSEQ T-MAP offering from COVID-19 into oncology.

This partnership enables Adaptive to utilize its database of over 58 billion immune cell receptors to provide T-cell receptor-antigen mapping data. This data may enhance treatment decisions and facilitate earlier disease detection.

AstraZeneca will provide biological samples, and Adaptive will receive quarterly payments along with additional fees, with future options for further collaboration.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 1:30 p.m. PT / 4:30 p.m. ET. The presentation will showcase the company's advancements in translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment. Interested individuals can access a live and archived webcast via the company’s website. Adaptive Biotechnologies focuses on developing immune-driven clinical products aimed at treating various diseases including cancer and autoimmune conditions.

Adaptive Biotechnologies presents new data on its clonoSEQ Assay for assessing minimal residual disease (MRD) in patients with multiple myeloma at the ASH Annual Meeting. This FDA-cleared test demonstrates high accuracy in detecting residual cancer cells post-treatment. A study showed that MRD-informed treatment decisions led to a median progression-free survival of 97 months versus 75 months without treatment adjustment (p=0.006). The clonoSEQ Assay not only enhances patient outcomes but also offers potential cost savings, estimated at $916,000 annually per patient.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will present over 35 abstracts regarding its clonoSEQ® Assay at the ASH virtual 62nd Annual Meeting from December 5-8, 2020. This FDA-cleared assay assesses minimal residual disease (MRD) in blood cancers, including chronic lymphocytic leukemia (CLL) and multiple myeloma. Research indicates that MRD measurement correlates with enhanced patient outcomes and healthcare savings. The presentations aim to reinforce clonoSEQ as a vital tool for improving treatment decisions and patient management in hematologic malignancies.